BioAtla (BCAB) Expected to Announce Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) is anticipated to post its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect BioAtla to post earnings of ($0.36) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

BioAtla Price Performance

Shares of BCAB opened at $0.16 on Thursday. BioAtla has a one year low of $0.13 and a one year high of $1.43. The firm has a market capitalization of $10.15 million, a P/E ratio of -0.14 and a beta of 1.08. The business has a fifty day moving average of $0.23 and a 200 day moving average of $0.56.

Analyst Upgrades and Downgrades

BCAB has been the topic of several recent research reports. Rodman & Renshaw began coverage on shares of BioAtla in a research note on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAtla in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Hedge Funds Weigh In On BioAtla

A number of hedge funds have recently made changes to their positions in the business. Woodline Partners LP purchased a new stake in shares of BioAtla during the first quarter worth about $26,000. Acadian Asset Management LLC lifted its holdings in BioAtla by 968.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock worth $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Vanguard Group Inc. boosted its stake in BioAtla by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after purchasing an additional 162,647 shares during the period. Millennium Management LLC bought a new position in BioAtla in the 3rd quarter worth approximately $235,000. Finally, Susquehanna International Group LLP grew its holdings in BioAtla by 237.6% during the 3rd quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares in the last quarter. Institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.